{"slug":"semaglutide-ibd","verification":{"valid":true,"entries":5,"head":"6fb1df07d3f1d4447bea8170bb2bcfb630ffccf40d1eb7036901a5a3793cf110"},"count":5,"sources":[{"id":"s19","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/38642103/","title":"Effectiveness and Safety of Semaglutide for Weight Loss in Patients With Inflammatory Bowel Disease and Obesity","quote":"Semaglutide use is effective in patients with IBD and obesity similar to patients without IBD, with >5% mean weight loss. There was no increased risk of IBD-specific adverse events with semaglutide use.","summary":"Retrospective cohort study using TriNetX database; matched IBD vs non-IBD obese patients on semaglutide.","claim_ids":["c1"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:25:23.413Z","link_status":"ok","quote_status":"unverified","prev":"genesis","hash":"018ff29ce24aa4442d90f928732f65a84fa4187f4c9e5cc3d89203691d246731"},{"id":"s20","type":"news","url":"https://www.docwirenews.com/post/the-potential-of-glp-1-receptor-agonists-for-management-of-inflammatory-bowel-disease","title":"The Potential of GLP-1 Receptor Agonists for Management of Inflammatory Bowel Disease","quote":"the use of glucagon-like peptide 1 receptor agonists (GLP1RA) was associated with improved inflammatory bowel disease (IBD)-related outcomes among patients with ulcerative colitis (UC) and Crohn’s disease (CD).","summary":"Real-world database study of 580 IBD patients on GLP-1 RAs vs matched controls showing lower adverse outcomes.","claim_ids":["c2"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:25:23.413Z","link_status":"ok","quote_status":"verified","prev":"018ff29ce24aa4442d90f928732f65a84fa4187f4c9e5cc3d89203691d246731","hash":"63ad2d05bf749ee5b35f211c2a06c9ec041cd3986f35a44a50b3384b5d44cdf6"},{"id":"s28","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13061526/","title":"Semaglutide-Induced Symptomatic Remission in Ulcerative Colitis","quote":"We report a 42-year-old woman with left-sided UC and poorly controlled diabetes who achieved remission after initiating semaglutide.","summary":"Single case report of UC remission post-semaglutide.","claim_ids":["c3"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:25:23.413Z","link_status":"ok","quote_status":"unverified","prev":"63ad2d05bf749ee5b35f211c2a06c9ec041cd3986f35a44a50b3384b5d44cdf6","hash":"427919689715ce08e9fe2e570f345d88868d5df3f71420847ec2a18c4de519d1"},{"id":"s39","type":"other","url":"https://www.fellahealth.com/guide/semaglutide-and-crohns","title":"Semaglutide and Crohn's Disease: Safety, Risks, and What Research Says","quote":"A 2019 study in experimental colitis models demonstrated that GLP-1 receptor activation reduced inflammatory markers and improved intestinal barrier function.","summary":"Mentions preclinical colitis model findings.","claim_ids":["c4"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:25:23.413Z","link_status":"ok","quote_status":"verified","prev":"427919689715ce08e9fe2e570f345d88868d5df3f71420847ec2a18c4de519d1","hash":"a067d581ef8ba3337292d56ffa737c008be87d1bcaffe2870447f18242f101c1"},{"id":"s23","type":"other","url":"https://www.fellahealth.com/guide/semaglutide-and-crohns","title":"Semaglutide and Crohn's Disease: Safety, Risks, and What Research Says","quote":"Current research specifically examining semaglutide or other GLP-1 receptor agonists in patients with inflammatory bowel disease remains limited. The pivotal clinical trials for semaglutide (SUSTAIN and STEP programs) did not specifically enroll or report outcomes for patients with Crohn's disease or ulcerative colitis.","summary":"Highlights absence of dedicated RCTs in IBD.","claim_ids":["c5"],"found_by":"grok/grok-4.3","extra":{},"accessed_at":"2026-06-30T00:25:23.413Z","link_status":"ok","quote_status":"verified","prev":"a067d581ef8ba3337292d56ffa737c008be87d1bcaffe2870447f18242f101c1","hash":"6fb1df07d3f1d4447bea8170bb2bcfb630ffccf40d1eb7036901a5a3793cf110"}]}